VCYT

Veracyte, Inc.

A maker of genomic tests that help doctors decide how to treat cancer, Veracyte reads a patient's tumor biology to answer questions like whether a thyroid nodule is benign or a prostate cancer needs aggressive treatment. Its best-known products are the Afirma thyroid test and the Decipher prostate test. Founded in 2006 as Calderome and renamed in 2008, the company's name blends the Latin for "truth" with the Greek suffix for "cell" — a nod to revealing what a patient's cells actually say.

Recent Activity

Show $

2026Q2

5 sells

ARK Genomic Revolution ETFTRIM

-97.4K shares(-8.9%)

ARK Genomic Revolution ETFTRIM

-97.4K shares(-8.9%)

ARK Innovation ETFTRIM

-477.6K shares(-21.3%)

ARK Innovation ETFTRIM

-477.6K shares(-21.3%)

ARK InvestTRIM

-757.9K shares(-24.8%)

ARK InvestTRIM

-757.9K shares(-24.8%)

ArrowMark PartnersTRIM

-932.1K shares(-67.8%)

ArrowMark PartnersTRIM

-932.1K shares(-67.8%)

Bridgewater Associates LPTRIM

-33.3K shares(-36.4%)

Bridgewater Associates LPTRIM

-33.3K shares(-36.4%)

2026Q1

1 buy4 sells

ARK Genomic Revolution ETFTRIM

-34.9K shares(-3.1%)

ARK Genomic Revolution ETFTRIM

-34.9K shares(-3.1%)

ARK Innovation ETFTRIM

-624.3K shares(-21.8%)

ARK Innovation ETFTRIM

-624.3K shares(-21.8%)

ARK InvestTRIM

-833.7K shares(-21.4%)

ARK InvestTRIM

-833.7K shares(-21.4%)

ArrowMark PartnersTRIM

-187.3K shares(-12.0%)

ArrowMark PartnersTRIM

-187.3K shares(-12.0%)

Bridgewater Associates LPADD

+63.2K shares(+222.6%)

Bridgewater Associates LPADD

+63.2K shares(+222.6%)

Loading more activity...